Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPSC Century Therapeutics	$0.48 +2.3%	$0.55	$0.34 ▼ $1.86	$40.45M	1.78	695,160 shs	768,498 shs
MCRB Seres Therapeutics	$18.80 +1.6%	$14.88	$6.53 ▼ $26.40	$161.96M	0.15	117,663 shs	81,112 shs
NVCT Nuvectis Pharma	$6.52 +2.7%	$7.15	$4.44 ▼ $11.80	$161.65M	-0.27	87,887 shs	49,476 shs
SXTC China SXT Pharmaceuticals	$1.38 -6.1%	$1.61	$0.95 ▼ $7.84	$170.56M	1.35	22,280 shs	45,198 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPSC Century Therapeutics	+2.26%	-4.26%	-14.19%	-22.31%	-69.89%
MCRB Seres Therapeutics	+1.62%	-1.00%	+31.65%	+128.43%	+14.68%
NVCT Nuvectis Pharma	+2.68%	-0.15%	-5.51%	-26.33%	-1.36%
SXTC China SXT Pharmaceuticals	-6.12%	-5.48%	-12.66%	-33.97%	-71.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPSC Century Therapeutics	$0.48 +2.3%	$0.55	$0.34 ▼ $1.86	$40.45M	1.78	695,160 shs	768,498 shs
MCRB Seres Therapeutics	$18.80 +1.6%	$14.88	$6.53 ▼ $26.40	$161.96M	0.15	117,663 shs	81,112 shs
NVCT Nuvectis Pharma	$6.52 +2.7%	$7.15	$4.44 ▼ $11.80	$161.65M	-0.27	87,887 shs	49,476 shs
SXTC China SXT Pharmaceuticals	$1.38 -6.1%	$1.61	$0.95 ▼ $7.84	$170.56M	1.35	22,280 shs	45,198 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPSC Century Therapeutics	+2.26%	-4.26%	-14.19%	-22.31%	-69.89%
MCRB Seres Therapeutics	+1.62%	-1.00%	+31.65%	+128.43%	+14.68%
NVCT Nuvectis Pharma	+2.68%	-0.15%	-5.51%	-26.33%	-1.36%
SXTC China SXT Pharmaceuticals	-6.12%	-5.48%	-12.66%	-33.97%	-71.30%

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IPSC Century Therapeutics	$6.59M	6.28	N/A	N/A	$1.90 per share	0.25
MCRB Seres Therapeutics	$126.32M	1.30	N/A	N/A	$1.61 per share	11.68
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.50 per share	N/A
SXTC China SXT Pharmaceuticals	$1.74M	92.02	N/A	N/A	$21.35 per share	0.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IPSC Century Therapeutics	-$126.57M	-$0.29	N/A	N/A	N/A	-19.10%	-11.53%	-6.94%	11/4/2025 (Estimated)
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-350.16%	-67.69%	11/12/2025 (Estimated)
NVCT Nuvectis Pharma	-$19M	-$1.17	N/A	N/A	N/A	N/A	-150.81%	-94.84%	11/4/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.30M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest IPSC, SXTC, NVCT, and MCRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	IPSC Century Therapeutics	-$0.38	-$0.38	N/A	-$0.38	$0.03 million	N/A
8/6/2025	Q2 2025	MCRB Seres Therapeutics	-$2.72	-$2.27	+$0.45	-$2.27	$11.75 million	N/A
8/5/2025	Q2 2025	NVCT Nuvectis Pharma	-$0.25	-$0.30	-$0.05	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IPSC Century Therapeutics	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IPSC Century Therapeutics	N/A	10.72	10.72
MCRB Seres Therapeutics	N/A	1.57	1.57
NVCT Nuvectis Pharma	N/A	2.66	2.66
SXTC China SXT Pharmaceuticals	0.01	3.54	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IPSC Century Therapeutics	50.20%
MCRB Seres Therapeutics	59.34%
NVCT Nuvectis Pharma	96.77%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
IPSC Century Therapeutics	5.00%
MCRB Seres Therapeutics	4.70%
NVCT Nuvectis Pharma	30.52%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IPSC Century Therapeutics	170	86.39 million	82.07 million	Optionable
MCRB Seres Therapeutics	330	8.75 million	8.34 million	Optionable
NVCT Nuvectis Pharma	8	25.46 million	17.69 million	Not Optionable
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable

IPSC, SXTC, NVCT, and MCRB Headlines

Recent News About These Companies

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock Price Down 5.7% - What's Next?

August 27, 2025 | marketbeat.com

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Up 48.3% in July

August 21, 2025 | marketbeat.com

China SXT Pharmaceuticals Full Year 2025 Earnings: US$2.32 loss per share (vs US$28.58 loss in FY 2024)

August 2, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Inc. (SXTC) Stock Price Today - WSJ

July 30, 2025 | wsj.com

China SXT Pharmaceuticals, Inc. (SXTC) - Yahoo Finance

July 4, 2025 | sg.finance.yahoo.com

China SXT Pharmaceuticals Inc News (SXTC) - Investing.com

June 25, 2025 | investing.com

China SXT Pharmaceuticals Issues 90 Million Shares Following Warrant Exercise

June 16, 2025 | tipranks.com

China SXT Pharmaceuticals Inc Ordinary Shares

April 23, 2025 | morningstar.comM

China SXT Pharmaceuticals Reports Financial Results Amid Regulatory Challenges

March 28, 2025 | tipranks.com

China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange

March 19, 2025 | tipranks.com

China SXT Pharmaceuticals regains compliance with Nasdaq

March 17, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

March 17, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

March 17, 2025 | globenewswire.com

China SXT Pharmaceuticals Inc trading resumes

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, volatility trading pause

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, news pending

February 24, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Announces New Securities Purchase Agreement

January 27, 2025 | msn.com

China SXT Pharmaceuticals Inc (SXTC) Stock’s 0.02% Increase This Year: What’s the Story?

January 7, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock Price Reaches $0.51: What Factors Are Influencing This Level?

January 1, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock: Greater Than Its Current Valuation?

December 26, 2024 | bovnews.comB

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

October 7, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC, SXTC, NVCT, and MCRB Company Descriptions

Century Therapeutics NASDAQ:IPSC

$0.48 +0.01 (+2.26%)

Closing price 09/4/2025 04:00 PM Eastern

Extended Trading

$0.48 0.00 (-0.17%)

As of 09/4/2025 07:56 PM Eastern

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Seres Therapeutics NASDAQ:MCRB

$18.80 +0.30 (+1.62%)

Closing price 09/4/2025 04:00 PM Eastern

Extended Trading

$18.75 -0.05 (-0.27%)

As of 09/4/2025 07:14 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Nuvectis Pharma NASDAQ:NVCT

$6.52 +0.17 (+2.68%)

Closing price 09/4/2025 04:00 PM Eastern

Extended Trading

$6.58 +0.06 (+0.84%)

As of 09/4/2025 06:48 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.38 -0.09 (-6.12%)

Closing price 09/4/2025 03:59 PM Eastern

Extended Trading

$1.36 -0.02 (-1.81%)

As of 09/4/2025 07:58 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPSC, SXTC, NVCT, and MCRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPSC, SXTC, NVCT, and MCRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC, SXTC, NVCT, and MCRB Company Descriptions

Century Therapeutics NASDAQ:IPSC

Seres Therapeutics NASDAQ:MCRB

Nuvectis Pharma NASDAQ:NVCT

China SXT Pharmaceuticals NASDAQ:SXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPSC, SXTC, NVCT, and MCRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPSC, SXTC, NVCT, and MCRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSC, SXTC, NVCT, and MCRB Company Descriptions

Century Therapeutics NASDAQ:IPSC

Seres Therapeutics NASDAQ:MCRB

Nuvectis Pharma NASDAQ:NVCT

China SXT Pharmaceuticals NASDAQ:SXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools